다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Altamira Therapeutics Ltd (CYTO)
Altamira Therapeutics Ltd (CYTO) 뉴스

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CYTO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/17	05:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/05/01	21:47	GlobeNewswire Inc.	Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/04/24	21:47	GlobeNewswire Inc.	Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/04/10	21:00	GlobeNewswire Inc.	Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/04/04	21:45	GlobeNewswire Inc.	Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/03/25	21:47	GlobeNewswire Inc.	Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/02/07	22:47	GlobeNewswire Inc.	Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/24	22:47	GlobeNewswire Inc.	Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/23	07:02	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/22	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/20	06:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/20	06:40	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/20	06:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/09	07:02	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/08	22:47	GlobeNewswire Inc.	Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/29	22:47	GlobeNewswire Inc.	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/11	22:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/11	22:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/11	22:00	GlobeNewswire Inc.	Altamira Therapeutics Provides Investor and Business Update	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/08	23:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/06	02:54	GlobeNewswire Inc.	Altamira Therapeutics to Host Investor & Business Update Call on December 11th	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/30	00:20	GlobeNewswire Inc.	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/23	06:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/21	22:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/17	23:04	GlobeNewswire Inc.	Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/10	22:47	GlobeNewswire Inc.	Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/01	05:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/10/04	22:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/09/14	21:47	GlobeNewswire Inc.	Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/09/12	20:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd

검색 관련기사 보기:NASDAQ:CYTO

1 2 3 4 5 6 7 8 9 10 다음 >>

Alaska Energy Metals (QB)

Bon Natural Life

Turkish Basketball Federation Fa

Investment Grade MultiAs...

Cartier Resources

Vontobel Financial Produ...

Surgical Science Sweden Ab

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관